“Comforting and Encouraging” Study Shows JAK Inhibitors Not Linked to Short-Term Heart Woes in Derm Patients
The Dermatology Digest
FEBRUARY 11, 2024
By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE).
Let's personalize your content